abstract |
A biotherapeutic process for preparing a patient-specific cytotoxic composition against a malignant tumor. Immune B-cell lymphocytes are obtained from in vitro and/or in vivo immunization with tumor cells. The immune B-cells are fused with myeloma cells or B-lymphoblastoid cells to form hybridomas which are then tested for production of monoclonal antibodies against the tumor cells. A plurality of selected hybridomas, each generating tumor-selective antibodies, are isolated and cloned and are used to produce monoclonal antibodies in large amounts. These antibodies are combined in a monoclonal antibody "cocktail" that will react with substantially all the tumor cells. The monoclonal antibody cocktail is linked with a drug, toxin, isotope or biological substance to form an immunoconjugate preparation which can be used, after appropriate preclinical safety and activity testing, for treating the patient with a custom-tailored therapeutic agent. |